On October 9, 2025, Novo Nordisk announced its intention to acquire Akero Therapeutics for $54 a share in cash, with an additional $6 per share if Akero's lead drug, efruxifermin (EFX), receives U.S. FDA approval. This acquisition is valued at up to $5.2 billion.
This strategic move significantly expands Novo Nordisk's portfolio into the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease. EFX, Akero's experimental liver disease treatment, is a promising asset in this large and underserved market.
The acquisition underscores Novo Nordisk's commitment to diversifying its metabolic health offerings beyond diabetes and obesity. This investment aims to strengthen its pipeline and market position in a rapidly evolving therapeutic area, leveraging its existing expertise in metabolic diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.